We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Court Tosses $1.2 Billion Award for BMS in CAR-T Patent Dispute With Gilead
Court Tosses $1.2 Billion Award for BMS in CAR-T Patent Dispute With Gilead
A federal appeals court has reversed a $1.2 billion ruling which found Gilead Sciences’ cancer immunotherapy Yescarta (axicabtagene ciloleucel) infringed on a Bristol Myers Squibb (BMS) patent for CAR-T technology.